2-[4-[3-[2-[(4-Trifluoromethyl)phenyl]-4-isopropyl-5-thiazolyl]propionyl]phenyloxy]-2-methylpropionic acid | 400760-42-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-[4-[3-[2-[(4-Trifluoromethyl)phenyl]-4-isopropyl-5-thiazolyl]propionyl]phenyloxy]-2-methylpropionic acid
• 英文别名: 2-Methyl-2-[4-[3-[4-propan-2-yl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]propanoyl]phenoxy]propanoic acid
• CAS: 400760-42-1
• 化学式: C₂₆H₂₆F₃NO₄S
• 分子量: 505.558
• InChiKey: BHGASKXGNAIIQI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  35
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  105
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• Ppar delta activators
  申请人：——

  公开号：US20040097739A1

  公开（公告）日：2004-05-20

  Compounds of the general formula (I) or salts thereof and activators of PPAR&dgr; (peroxisome proliferator activated receptor &dgr;) containing the compounds or the salts as the active ingredient: wherein R 1 and R 2 each are hydrogen, C 1-8 alkyl, an aryl or heterocyclic group which may be substituted, or the like; A is oxygen, sulfur, or the like; X 1 and X 2 are each a free valency, oxygen, S(O) p (wherein p is an integer of 0 to 2), C(═O), C(═O)NH, NHC(═O), CH═CH, or the like; Y is optionally substituted C 1-8 alkylene; Z is oxygen or sulfur; R 3 and R 4 are each optionally substituted C 1-8 alkyl; and R 8 is hydrogen or C 1-8 alkyl, with the proviso that when X 1 is a free valency, X 2 is not O or S(O) p , while when X 1 is C(═O)NH, X 2 is not a free valency. 1

  通式（I）的化合物或其盐以及PPARδ（过氧化物酶体增殖物激活受体δ）激活剂，其中化合物或盐为活性成分：其中R1和R2分别为氢，C1-8烷基，取代的芳基或杂环基等；A为氧，硫等；X1和X2分别为自由价，氧，S（O）p（其中p为0至2的整数），C（═O），C（═O）NH，NHC（═O），CH═CH或类似物；Y为可选的取代的C1-8烷基；Z为氧或硫；R3和R4分别为可选的取代的C1-8烷基；而R8为氢或C1-8烷基，但当X1为自由价时，X2不为O或S（O）p，而当X1为C（═O）NH时，X2不为自由价。
• Use of PPAR Delta Ligands for the Treatment or Prevention of Inflammation or Energy Metabolism/Production Related Diseases
  申请人：Barbaras Ronald

  公开号：US20110092517A1

  公开（公告）日：2011-04-21

  Provided herein are methods for treatment, prevention, or amelioration of one or more symptoms of a disease or condition related to disorders of insulin and/or glucose metabolism, inflammatory conditions, mitochondrial disease, muscle disorders, or pulmonary disorders, involving administering a PPARδ agonist or a pharmaceutical composition comprising a PPARδ agonist. In one embodiment, the disease or condition is selected from myopathy, inflammatory vascular diseases, Parkinson's and Alzheimer's diseases, systemic inflammatory disorders, renal ischemia, inflammatory rheumatic disorders, and inflammatory diseases of the lung. In another embodiment, methods for increasing oxidative muscle fibers, reducing mitochondria disease, decreasing insulin resistance, decreasing plasma glucose, or decreasing weight, involving administering a PPARδ agonist or a pharmaceutical composition comprising a PPARδ agonist, are provided.

  本文提供了治疗、预防或改善与胰岛素和/或葡萄糖代谢紊乱、炎症性疾病、线粒体病、肌肉疾病或肺部疾病相关的一种或多种症状的方法，其中涉及给予一种PPARδ激动剂或含有PPARδ激动剂的制剂。在一种实施例中，所述疾病或症状被选自肌无力、炎症性血管疾病、帕金森和阿尔茨海默病、全身性炎症性疾病、肾脏缺血、炎症性风湿病和肺部炎症性疾病。在另一种实施例中，提供了通过给予PPARδ激动剂或含有PPARδ激动剂的制剂来增加氧化肌纤维、减少线粒体疾病、降低胰岛素抵抗、降低血浆葡萄糖或减轻体重的方法。
• PPAR (delta) ACTIVATORS
  申请人：NIPPON CHEMIPHAR CO., LTD.

  公开号：EP1310494B1

  公开（公告）日：2012-01-25
• USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES
  申请人：Cerenis Therapeutics S.A.

  公开号：EP2464349A2

  公开（公告）日：2012-06-20
• [EN] USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES<br/>[FR] UTILISATION DES LIGANDS PPAR? DANS LE TRAITEMENT OU LA PRÉVENTION D'INFLAMMATIONS OU DE MALADIES ASSOCIÉES AU MÉTABOLISME/PRODUCTION ÉNERGÉTIQUE
  申请人：CERENIS THERAPEUTICS S A

  公开号：WO2011020001A2

  公开（公告）日：2011-02-17

  Provided herein are methods for treatment, prevention, or amelioration of one or more symptoms of a disease or condition related to disorders of insulin and/or glucose metabolism, inflammatory conditions, mitochondrial disease, muscle disorders, or pulmonary disorders, involving administering a PPARδ agonist or a pharmaceutical composition comprising a PPARδ agonist. In one embodiment, the disease or condition is selected from myopathy, inflammatory vascular diseases, Parkinson's and Alzheimer's diseases, systemic inflammatory disorders, renal ischemia, inflammatory rheumatic disorders, and inflammatory diseases of the lung. In another embodiment, methods for increasing oxidative muscle fibers, reducing mitochondria disease, decreasing insulin resistance, decreasing plasma glucose, or decreasing weight, involving administering a PPARδ agonist or a pharmaceutical composition comprising a PPARδ agonist, are provided.